Salem Radio Network News Monday, November 16, 2026

Health

LEO Pharma owners see market conditions as unsuitable for IPO, CEO says

Carbonatix Pre-Player Loader

Audio By Carbonatix

By Jesus Calero

Nov 16 (Reuters) – LEO Pharma’s owners don’t think the current market conditions support a stock market listing, its chief executive said on Monday, casting further doubt on the Danish drugmaker’s flotation plans for 2026.

Christophe Bourdon told Reuters that an initial public offering remained a “natural and viable option” for the dermatology specialist, while saying that its timing depended both on the company’s performance and investors’ appetite for new listings.

“The timing of a potential IPO is really in the hands of the two shareholders,” Bourdon said, referring to majority owner LEO Foundation with an 80% stake and private equity firm Nordic Capital, which owns the rest.

Bourdon said the owners considered the market environment unsuitable for a listing, without setting out a timetable for when one might take place.

Equity market volatility is growing as investors become more cautious, which has also prompted other companies to delay or scale back planned listings.

LEO Pharma’s plans for a market debut appeared to be gathering momentum earlier this year, with media reports suggesting it had selected banks to arrange a potential Copenhagen listing before the end of 2026.

However, more recent reports earlier in November said that market volatility could push the IPO into 2027. LEO Pharma declined to comment on the speculation at the time.

Bourdon said on Monday the company’s focus remained on delivering consistent growth and strengthening its business, so that it would be prepared to go public when conditions were right.

Nordic Capital invested €450 million ($496 million) in LEO Pharma in 2021, taking a minority stake as the drugmaker set out plans to prepare for a potential listing within four to five years.

LEO Pharma, which specialises in treatments for skin diseases, has since expanded its portfolio through acquisitions and new drug launches, including eczema treatment Anzupgo and psoriasis drug Spevigo. 

($1 = 0.9073 euros)

(Reporting by Jesus Calero in Gdansk, editing by Milla Nissi-Prussak)

Previous
Next
The Media Line News
X CLOSE